Drug profile · INN
catridecacog
NOVOTHIRTEEN
catridecacog (NOVOTHIRTEEN) is a coagulation factor xiii exogenous protein.
EMA: approved PMDA: approved Blood and blood forming organs (B02) B02BD11
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — catridecacog
- Class
- Blood and blood forming organs (B02)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
catridecacog (NOVOTHIRTEEN) is a coagulation factor xiii exogenous protein.
Key facts
INN catridecacog
Brand NOVOTHIRTEEN
Mechanism Coagulation factor XIII exogenous protein
Target Coagulation factor XIII A chain
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD11
Mechanism of action
Coagulation factor XIII exogenous protein
Primary target: Coagulation factor XIII A chain
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is catridecacog?
catridecacog (NOVOTHIRTEEN) is a coagulation factor xiii exogenous protein.
What is the brand name for catridecacog?
NOVOTHIRTEEN is a marketed brand name for catridecacog. Check FDA Drugs@FDA for the current US label holder and prescribing information.